Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312818 | 1.00 | CASR (1.00) | CASRLMNAKMT2AAKR1C3AKR1C2 | |
| SCHEMBL3930340 | 1.00 | CASR (1.00) | CASRLMNAKMT2AAKR1C3AKR1C2 | |
| SCHEMBL5083151 | 0.91 | CASR (0.84) | CASRLMNAKMT2AAKR1C3AKR1C2 | |
| SCHEMBL3923082 | 0.90 | CASR (1.00) | CASRKMT2AAKR1C3AKR1C2TMEM97 | |
| SCHEMBL5498394 | 0.89 | CASR (0.81) | CASRTMEM97 | |
| SCHEMBL3930371 | 0.89 | CASR (1.00) | CASRTMEM97 | |
| SCHEMBL3879837 | 0.89 | CASR (0.81) | CASRTMEM97 | |
| SCHEMBL3931202 | 0.89 | CASR (1.00) | CASRTMEM97 | |
| SCHEMBL3920766 | 0.89 | CASR (1.00) | CASRKMT2AAKR1C3AKR1C2TMEM97 | |
| SCHEMBL3934399 | 0.89 | CASR (1.00) | CASRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093299-B2 | Methods of treating bowel disorders | AMGEN INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-20110144102-A1 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY | AMGEN INC. | 2011-06-16 | — | — | US | claimed |
| EP-2037736-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASES | Indiana University Research and Technology Corporation (US) | 2009-03-25 | — | — | EP | claimed |
| US-20090018135-A1 | Methods of treating bowel disorders | AMGEN INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1937233-A2 | METHODS OF MODULATING INTESTINAL FLUID BALANCE USING CALCIOLYTICS OR CALCIMIMETICS | Amgen Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2008008650-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2008-01-17 | — | — | WO | claimed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | claimed |
| WO-2007027548-A9 | METHODS OF MODULATING INTESTINAL FLUID BALANCE | AMGEN INC (US) | 2007-07-12 | — | — | WO | claimed |
| WO-2007027548-A2 | METHODS OF MODULATING INTESTINAL FLUID BALANCE | AMGEN INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | claimed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | claimed |
| US-8779004-B2 | Stable emulsion formulations | AMGEN, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779004-B2 | Stable emulsion formulations | AMGEN, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2139462-B1 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8486381-B2 | Methods of modulating intestinal fluid balance | AMGEN INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2007027548-A2 | METHODS OF MODULATING INTESTINAL FLUID BALANCE | AMGEN INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006102061-A2 | METHODS OF DECREASING CALCIFICATION | AMGEN INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | CASR 2/4885LMNA 3732/4885KMT2A 3976/4885 |
| US-20090018135-A1 | Methods of treating bowel disorders | SLC10A2, FABP2, ALPI | CASR 224/4885LMNA 2647/4885KMT2A 3994/4885 |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | CALCR, CALCB, CALCRL | CASR 153/4885LMNA 3745/4885KMT2A 4722/4885 |
| US-20110144102-A1 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY | HIF1AN, HIF1A, CASR | CASR 3/4885LMNA 2928/4885KMT2A 4662/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | CASR 24/4885LMNA 2825/4885KMT2A 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.